Transforming growth factor-[beta]1 regulates steady-state PTH/PTHrP receptor mRNA levels and PTHrP binding in ROS 17/2.8 osteosarcoma cells
dc.contributor.author | McCauley, Laurie K. | en_US |
dc.contributor.author | Beecher, Christopher A. | en_US |
dc.contributor.author | Melton, Mary E. | en_US |
dc.contributor.author | Werkmeister, James R. | en_US |
dc.contributor.author | Juppner, Harald | en_US |
dc.contributor.author | Abou-Samra, Abdul-Badi | en_US |
dc.contributor.author | Segre, Gino V. | en_US |
dc.contributor.author | Rosol, Thomas J. | en_US |
dc.date.accessioned | 2006-04-10T18:11:39Z | |
dc.date.available | 2006-04-10T18:11:39Z | |
dc.date.issued | 1994-05 | en_US |
dc.identifier.citation | McCauley, Laurie K., Beecher, Christopher A., Melton, Mary E., Werkmeister, James R., Juppner, Harald, Abou-Samra, Abdul-Badi, Segre, Gino V., Rosol, Thomas J. (1994/05)."Transforming growth factor-[beta]1 regulates steady-state PTH/PTHrP receptor mRNA levels and PTHrP binding in ROS 17/2.8 osteosarcoma cells." Molecular and Cellular Endocrinology 101(1-2): 331-336. <http://hdl.handle.net/2027.42/31617> | en_US |
dc.identifier.uri | http://www.sciencedirect.com/science/article/B6T3G-47NWGNK-K2/2/cecbbbc2101c572eb8c7c3185b69d61d | en_US |
dc.identifier.uri | https://hdl.handle.net/2027.42/31617 | |
dc.identifier.uri | http://www.ncbi.nlm.nih.gov/sites/entrez?cmd=retrieve&db=pubmed&list_uids=9397968&dopt=citation | en_US |
dc.description.abstract | The effect of transforming growth factor [beta]1 (TGF-[beta]1) on the expression of mRNA for the parathyroid hormone receptor and binding of iodinated parathyroid hormone-related protein in ROS 17/2.8 osteosarcoma cells was evaluated. TGF-[beta]1 stimulated a 2-7-fold increase in steady state mRNA levels for the parathyroid hormone receptor at a maximal dose of 5 ng/ml, with increased levels of expression at 6 h of TGF-[beta]1-incubation, and peak levels at 8-24 h. Receptor binding studies revealed a significant increase in PTHrP-specific binding with TGF-[beta]1 doses as low as 0.5 ng/ml and a 55% increase in numbers of receptors with no alteration in binding affinity with 5.0 ng/ml TGF-[beta]1. Time course studies indicated that receptor binding was increased at 24 h with peak levels reached at 48 h of treatment. PTH-stimulated cAMP levels were significantly increased in ROS 17/2.8 cells treated with TGF-[beta]1 (0.5 ng/ml) for 48 h. These data indicate that TGF-[beta]1 upregulates steady-state mRNA, ligand binding and PTH/PTHrP receptor signaling in rat osteosarcoma cells. The effects of TGF-[beta]1 on bone may be attributed in part to regulation of the PTH/PTHrP receptor at the molecular level. | en_US |
dc.format.extent | 832055 bytes | |
dc.format.extent | 3118 bytes | |
dc.format.mimetype | application/pdf | |
dc.format.mimetype | text/plain | |
dc.language.iso | en_US | |
dc.publisher | Elsevier | en_US |
dc.title | Transforming growth factor-[beta]1 regulates steady-state PTH/PTHrP receptor mRNA levels and PTHrP binding in ROS 17/2.8 osteosarcoma cells | en_US |
dc.type | Article | en_US |
dc.rights.robots | IndexNoFollow | en_US |
dc.subject.hlbsecondlevel | Public Health | en_US |
dc.subject.hlbsecondlevel | Internal Medicine and Specialties | en_US |
dc.subject.hlbsecondlevel | Biological Chemistry | en_US |
dc.subject.hlbtoplevel | Science | en_US |
dc.subject.hlbtoplevel | Health Sciences | en_US |
dc.description.peerreviewed | Peer Reviewed | en_US |
dc.contributor.affiliationum | Department of Periodontology/Prevention and Geriatrics, The University of Michigan, 1011 N. University Ave., 48109-1078, Ann Arbor, MI, USA | en_US |
dc.contributor.affiliationum | Department of Periodontology/Prevention and Geriatrics, The University of Michigan, 1011 N. University Ave., 48109-1078, Ann Arbor, MI, USA | en_US |
dc.contributor.affiliationother | Department of Medicine, Division of Endocrinology, Thomas Jefferson University, Philadelphia, PA, USA | en_US |
dc.contributor.affiliationother | Department of Veterinary Pathobiology, The Ohio State University, Columbus, OH, USA | en_US |
dc.contributor.affiliationother | Endocrine Unit, Department of Medicine, The Massachusetts General Hospital and Harvard Medical School, Boston, MA, USA | en_US |
dc.contributor.affiliationother | Endocrine Unit, Department of Medicine, The Massachusetts General Hospital and Harvard Medical School, Boston, MA, USA | en_US |
dc.contributor.affiliationother | Endocrine Unit, Department of Medicine, The Massachusetts General Hospital and Harvard Medical School, Boston, MA, USA | en_US |
dc.contributor.affiliationother | Department of Veterinary Pathobiology, The Ohio State University, Columbus, OH, USA | en_US |
dc.identifier.pmid | 9397968 | en_US |
dc.description.bitstreamurl | http://deepblue.lib.umich.edu/bitstream/2027.42/31617/1/0000549.pdf | en_US |
dc.identifier.doi | http://dx.doi.org/10.1016/0303-7207(94)90250-X | en_US |
dc.identifier.source | Molecular and Cellular Endocrinology | en_US |
dc.owningcollname | Interdisciplinary and Peer-Reviewed |
Files in this item
Remediation of Harmful Language
The University of Michigan Library aims to describe library materials in a way that respects the people and communities who create, use, and are represented in our collections. Report harmful or offensive language in catalog records, finding aids, or elsewhere in our collections anonymously through our metadata feedback form. More information at Remediation of Harmful Language.
Accessibility
If you are unable to use this file in its current format, please select the Contact Us link and we can modify it to make it more accessible to you.